[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100321149":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":24,"locations":25,"responsibleParty":36,"collaborators":24,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":24,"eligibilityCriteria":44,"healthyVolunteers":45,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":24,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":24,"overallStatus":58,"whyStopped":24,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"Jeil Pharmaceutical Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group I","EXPERIMENTAL","Period I: administration of telmisartan\u002FAmlodipine for 10 days then administration of telmisartan\u002Famlodipine and atorvastatin for 4 days Period II: atorvastatin for 4 days",[13],"Drug: telmisartan\u002Famlodipine and atorvastatin",{"label":15,"type":10,"description":16,"interventionNames":17},"Group II","Period I: administration of atorvastatin for 4 days Period II: administration of telmisartan\u002Famlodipine for 10 days then administration of telmisartan\u002Famlodipine and atorvastatin for 4 days",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","telmisartan\u002Famlodipine and atorvastatin","Telmisartan\u002FAmlodipine(40\u002F5 mg) 2 Tab for 10 days Telmisartan\u002FAmlodipine(40\u002F5 mg) 2 Tab with Atorvastatin 40 mg 1 Tab for 4 days Atorvastatin 40 mg 1 Tab for 4 days",[9,15],null,[26],{"facility":27,"status":24,"city":28,"state":24,"zip":24,"country":29,"countryCode":24,"cosmosGeoPoint":30,"geoPoint":35,"contacts":24},"Samsung Medical Center","Seoul","South Korea",{"type":31,"coordinates":32},"Point",[33,34],126.9784,37.566,{"lat":34,"lon":33},{"type":37,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100321149","phase-1-drug-drug-interaction-following-oral-administration-of-telmisartanamlodipine-and-atorvastatin-in-healthy-adult-volunteers-100321149",false,"NCT03461081","Drug-drug Interaction Following Oral Administration of Telmisartan\u002FAmlodipine and Atorvastatin in Healthy Adult Volunteers","An Open-label, Randomized, Two-sequence, Multiple-dose, Crossover Study to Evaluate Drug-drug Interaction Following Oral Administration of Telmisartan\u002FAmlodipine and Atorvastatin in Healthy Adult Volunteers","Inclusion Criteria:\n\n* 19\\~55 years healthy male\n* The result of Body Mass Index(BMI) is not less than 19 kg\u002Fm2 , no more than 27 kg\u002Fm2\n* Subjects who agree to keep contraceptive methods during the clinical trial.\n\nExclusion Criteria:\n\n* Subjects who are allergic to investigational drug.\n* Subjects who have a medical history which can affect the clinical trial.\n* Hypertension(Systolic BP ≥ 150mmHG or Diastolic BP ≥ 100mmHg), Hypotension(Systolic BP ≤ 100mmHg or Diastolic BP ≤ 70mmHg)\n* Liver enzyme (AST, ALT) level exceeds the maximum normal range more than one and a half times.",true,"MALE","19 Years","55 Years",{"count":50,"type":51},32,"ACTUAL","INTERVENTIONAL",[54],"PHASE1","study to evaluate drug-drug interaction following oral administration of telmisartan\u002Famlodipine and atorvastatin in healthy adult volunteers",[57],"Hypertension With Hyperlipidemia","COMPLETED","2018-03-08",{"date":61,"type":51},"2018-03-12",{"date":63,"type":51},"2017-05-07",{"date":65,"type":51},"2017-12-12",{"name":5,"class":6},1]